Arca Biopharma (ABIO)

Arca Biopharma Stock Analysis & Ratings

ABIO Stock Chart & Stats

Day’s Range$2.25 - $2.35
52-Week Range$1.71 - $3.90
Previous Close$2.35
Average Volume (3M)147.86K
Market Cap$33.00M
P/E Ratio-1.8
Next EarningsAug 04, 2022
EPS ForecastN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
Smart Score5
EPS (TTM)-1.28

Arca Biopharma News

Currently, no data available
Please return soon. This page is being updated.




P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Arca Biopharma’s price range in the past 12 months?
Arca Biopharma lowest stock price was $1.71 and its highest was $3.90 in the past 12 months.
    What is Arca Biopharma’s market cap?
    Arca Biopharma’s market cap is $33.00M.
      What is Arca Biopharma’s price target?
      Currently, no data Available
      What do analysts say about Arca Biopharma?
      Not enough analysts have published a price target to provide an average price target.
      When is Arca Biopharma’s upcoming earnings report date?
      Arca Biopharma’s upcoming earnings report date is Aug 04, 2022 which is in 78 days.
        How were Arca Biopharma’s earnings last quarter?
        Arca Biopharma released its earnings results on May 02, 2022. The company reported -$0.227 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.227.
          Is Arca Biopharma overvalued?
          According to Wall Street analysts Arca Biopharma’s price is currently Overvalued.
            Does Arca Biopharma pay dividends?
            Arca Biopharma does not currently pay dividends.
            What is Arca Biopharma’s EPS estimate?
            Arca Biopharma’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Arca Biopharma have?
            Arca Biopharma has 14,410,000 shares outstanding.
              What happened to Arca Biopharma’s price movement after its last earnings report?
              Arca Biopharma reported an EPS of -$0.227 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.688%.
                Which hedge fund is a major shareholder of Arca Biopharma?
                Currently, no hedge funds are holding shares in ABIO


                Arca Biopharma Stock Analysis

                Smart Score
                Price Target
                No data currently available
                The Arca Biopharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Arca Biopharma

                ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

                Similar Stocks
                Price & Change
                Capricor Therapeutics

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis